Full-Time
Head of Transition
Grant Management Group
Posted on 9/21/2025
LGC Group
1,001-5,000 employees
Sells oligos, probes, primers, viral materials
No salary listed
Feltham, UK
In Person
 Operations & Logistics (1) |
|---|
- Proven track record in complex service mobilisation and transition management, preferably within a similar industry or context
- Strong project management skills, including experience in developing and managing project plans, budgets and timelines with diverse teams and structures
- Significant experience of working with HR and legal specialists to manage TUPE related activities including staff transfers in and out of an organisation
- Experience of delivering organisation culture change related activities and maintaining staff engagement during times of change
- Excellent communication, interpersonal and stakeholder management and engagement skills including with senior executives, policy makers, and delivery partners
- Experience of collaborating with other organisations to align transition plans with wider goals
- Solid experience in risk management and issue resolution
- Ability to lead in ambiguity, make evidence-based decisions, and drive clear outcomes in complex environments
- Commercial and financial literacy, including budget management, performance tracking, and value-for-money delivery
- Developing and Implementing Mobilisation Plans: Creating detailed plans, timelines and documentation for the contract(s), outlining the steps needed to move from contract award to full operational delivery
- Managing the Mobilisation Process: Overseeing all phases of mobilisation, ensuring activities are completed on schedule and within budget
- Risk Management: Identifying potential risks and issues associated with the mobilisation process, developing mitigation strategies in conjunction with other senior managers, and maintaining a risk register
- Stakeholder Management: Maintaining regular communication with internal and external stakeholders, managing expectations, and providing updates on progress
- Resource Management: Coordinating the allocation and utilisation of resources (people, equipment, etc.) to support the mobilisation process
- Ensuring Compliance: Ensuring all mobilisation activities comply with relevant regulations, company policies, and contractual obligations
- Leading and Motivating Teams: Providing leadership and guidance to the mobilisation team, fostering collaboration, and ensuring a positive and productive work environment
- Reporting and Documentation: Preparing regular progress reports for stakeholders, documenting key decisions and actions, and maintaining accurate records of mobilization activities
- Familiarity with the NIHR, UKRI, or similar scientific research commissioning environments
- Experience transitioning projects in politically sensitive or multi-agency contexts
- Understanding of healthcare commissioning, innovation funding, or public sector consultancy
- Strong grasp of change management principles, organisational design and cultural alignment strategies
- An ability to negotiate with customers and other service delivery organisations to agree cohesive plans for redesign and implementation of new and revised services
LGC Group provides life-sciences tools and services worldwide, including oligo components, probes, primers, recombinant viral materials, and proficiency-testing schemes for food safety. Its products support vaccine development, diagnostics, and therapies through mass spectrometry, immunoassays, and nucleic acid chemistry. It differentiates itself with a broad catalog of high-quality tools plus global proficiency-testing services and a wide customer base across diagnostics, healthcare, and pharma. Its goal is to improve healthcare outcomes and help create safer vaccines and treatments by delivering reliable tools and quality services.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
London, United Kingdom
Founded
1841
Simplify's Take
What believers are saying
- ChromaDex acquisition February 2026 adds 3,000 phytochemical standards boosting North America sales.
- Irish Horseracing Board renews LGC contract through 2027 for equine anti-doping analysis.
- CAD$100 million Canada synthesis center expands pharma research chemical capacity.
What critics are saying
- Merck KGaA erodes LGC market share with bundled CRMs at lower prices by Q1 2027.
- WADA 2026 protocol causes Fordham lab to lose 30% human sports testing to NSF by Q4 2026.
- USFDA revokes Lexington accreditation May 2026, forfeiting $50M horse racing contracts to Eurofins.
What makes LGC Group unique
- LGC's Informed-Sport certifies 440 products against 250+ banned substances using ISO 17025 labs.
- Lexington facility expanded November 2016 for equine doping control and US supplements testing.
- LoGiCal portfolio offers 3,000+ toxicology reference standards since 2012 launch.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Remote Work Options
Company News
LGC Group strengthens its reference material portfolio and North American reach with the acquisition of the ChromaDex Reference Standards business. The acquisition further enhances LGC's ability to support pharmaceutical, food, and testing laboratories with trusted reference materials that underpin safety, quality, and regulatory confidence. London, UK, 26 February 2026. LGC Group, a global leader in life sciences, diagnostics, and analytical solutions, today announced the acquisition of the ChromaDex Reference Standards portfolio from Niagen Bioscience (NASDAQ: NAGE). The acquisition expands LGC's reference materials offering and strengthens its commercial reach across North America. The acquisition brings an established portfolio of phytochemical reference materials for the dietary supplements industry into LGC, enabling direct engagement with a broad base of laboratory customers and strengthening LGC's ability to support pharmaceutical companies, testing laboratories, and food producers operating in regulated markets. Bruno Rossi, EVP & General Manager, LGC Standards, said: "The ChromaDex standards portfolio further enhances LGC's ability to support our pharmaceutical customers, testing laboratories, and food producers. Building on LGC's position as a world leader in reference materials and analytical standards, this acquisition expands our North American commercial reach and further supports customers in generating reliable data that safeguards product integrity and confidence across global supply chains." For over 25 years, the ChromaDex Reference Standards portfolio has been built on deep expertise in phytochemical characterisation and analytical verification. The portfolio includes over 3,000 phytochemical reference materials, spanning major classes such as alkaloids, flavonoids, terpenes, carotenoids, organic acids, stilbenoids, vitamins, and select botanicals and plant-based compounds. These materials are widely used to support ingredient verification, method development, authenticity testing, contamination detection, and routine quality control across complex global supply chains. Rob Fried, CEO of Niagen Bioscience, remarked, "This transaction reflects our disciplined focus on what we do best - advancing NAD+ science and delivering clinically proven, patented Niagen(R) solutions across consumer and clinical channels. Selling Reference Standards to LGC is a meaningful step in simplifying our business and ensuring we are allocating capital and talent toward the highest-impact opportunities for shareholders." The acquisition of the ChromaDex Reference Standards portfolio demonstrates LGC's commitment to providing trusted reference materials and measurement solutions that reinforce product safety, quality, and regulatory confidence, advancing its mission of Science for a Safer World. LGC is a global leader in life sciences, diagnostics, and analytical solutions. LGC Group work with partners around the world to address some of society's most important challenges, from diagnosing disease and enabling new treatments to supporting food security and protecting public health. Its science supports discovery, enables better health outcomes and helps safeguard the integrity of food, water, medicines and the environment. Every day, LGC Group provide the components, standards and services that laboratories, manufacturers and regulators rely on to make confident, evidence-based decisions. With operations in 14 countries and more than 180 years of scientific expertise, its work supports public health and sustainability at a global scale. From improving the accuracy of medical testing and verifying the safety of food products, to helping scientists develop the next generation of medicines, its solutions are trusted by customers in more than 170 countries. For further information please contact: Customer contact: Richard Pembrey Sales Director, LGC Standards +1 603 851 2834 Media contact: Magda Bartoszewicz Director Corporate Brand and Communications, LGC Group +44 7408 850 514
LGC Group has inaugurated a CAD$100 million (€61.5 million) Organic Chemistry Synthesis Centre of Excellence in Vaughan, canada, significantly expanding global capacity for advanced research chemicals to support the pharmaceutical and life sciences sectors.
Graham B Jackson Pty Ltd (GBJPL), an Australian leader in reference materials, partners with the globally renowned LGC Group to supply high-quality CRMs to laboratories across the country.
For example, LGC Group introduced a proficiency testing (PT) service in April 2020 that uses nucleic acid amplification testing to identify SARS-CoV-2 (COVID-19).
UK-based LGC, an international life sciences measurement and tools company, has appointed Joydeep Goswami as president and CEO, succeeding Euan O'Sullivan, who decided to step down from his role in early 2024 after fourteen years of service.